Edgar Filing: Currie Mark G - Form 4

Currie Mai	rk G										
Form 4											
February 0	3, 2011							<u></u>			
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION						NT	PPROVAL				
Check	Washington, D.C. 20549					Number:	3235-0287				
if no lo	nger							Expires:	January 31 2005		
subject Section Form 4	t to SIATEN n 16. 4 or	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					Estimated burden hou response	average Irs per			
-	Filed put	(a) of the l	Public U	Jtility Hol	ding Co		nge Act of 1934, of 1935 or Secti 940				
(Print or Typ	e Responses)										
1. Name and Address of Reporting Person <u>*</u> Currie Mark G			2. Issuer Name and Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
			IRONWOOD PHARMACEUTICALS INC [IRWD]								
(Last)	(First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year)				X Officer (gi below)	below)	· • •		
C/O IRON PHARMA BINNEY	CEUTICALS, IN	C., 301	02/01/2	-			Cme	I Scientific Offic	cer		
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
CAMBRI	DGE, MA 02142						Form filed by Person	More than One R	eporting		
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3,	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect		
				Code V		(D) Price					
Reminder: R	eport on a separate line	e for each cl	ass of sec	urities bene	•	•	•				
					inforr requi	nation cont red to resp	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

Edgar Filing: Currie Mark G - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) ((D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Employee Stock Option (Right to Buy)	\$ 11.11	02/01/2011		A	110,000		<u>(1)</u>	02/01/2021	Class A Common Stock	110,00

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Currie Mark G C/O IRONWOOD PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE, MA 02142			Chief Scientific Officer			
Signatures						

Signatures

C C 3 C

/s/ Halley E. Gilbert Attorney-in-Fact

02/03/2011

Date

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The option, granted as an annual performance award, vests as to 1.25% of the shares of Class A Common Stock on each monthly

(1) anniversary of January 1, 2011 for the first 36 months, and vests as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.